Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced its financial results for the first quarter ended March 31, 2014.
“The AMPYRA franchise remains strong, and we are reiterating our 2014 net sales guidance,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “During the quarter, a fifth AMPYRA patent was issued and listed in the Orange Book.
Help employers find you! Check out all the jobs and post your resume.
